Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $41.33

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $41.33.

OMCL has been the topic of several recent research reports. JPMorgan Chase & Co. increased their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Bank of America raised their price objective on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Saturday. Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Finally, Wells Fargo & Company boosted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th.

Institutional Trading of Omnicell

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its holdings in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares during the last quarter. GAMMA Investing LLC grew its stake in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the last quarter. EntryPoint Capital LLC grew its stake in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after purchasing an additional 1,345 shares during the last quarter. CWM LLC increased its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Finally, Benjamin Edwards Inc. raised its stake in shares of Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

OMCL stock opened at $40.47 on Tuesday. Omnicell has a 1-year low of $25.12 and a 1-year high of $45.84. The business has a 50-day moving average price of $43.22 and a 200 day moving average price of $34.42. The company has a market capitalization of $1.86 billion, a P/E ratio of -87.98, a PEG ratio of 47.11 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the previous year, the business posted $0.29 EPS. The company’s quarterly revenue was down 7.4% compared to the same quarter last year. As a group, equities research analysts forecast that Omnicell will post 0.64 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.